Phase II Multi-Centre, Randomized, Parallel Group, Pilot Trial to Compare the Incidence of Tocilizumab Related Infusion Reactions in Moderate to Severe RA Patients When Infusion is Made Over 1 Hour Against 31 Minutes.
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2014
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 04 May 2012 Status changed from active, no longer recruiting to completed, according to the European Clinical Trials Database.
- 18 May 2011 Planned end date changed from 1 Dec 2010 to 1 May 2011 as reported by ClinicalTrials.gov.